Welcome to our dedicated page for Calidi Biotherapeutics SEC filings (Ticker: CLDI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial updates, cash-burn tables, and stem-cell delivery jargon make Calidi Biotherapeutics’ SEC disclosures tough to navigate. Missing a single 8-K data point on a Phase 1 read-out could mean mispricing the stock. Stock Titan’s AI-driven platform removes that risk by translating every Calidi Biotherapeutics SEC filing into clear, actionable language—while the document is still hitting EDGAR.
Whether you need a Calidi Biotherapeutics quarterly earnings report 10-Q filing to track R&D spend, or a Calidi Biotherapeutics annual report 10-K simplified to understand liquidity runway, you’ll find it here—fully annotated. Our engine delivers:
- Real-time alerts for Calidi Biotherapeutics Form 4 insider transactions real-time so you can spot executive conviction.
- Concise explanations that make Calidi Biotherapeutics 8-K material events explained readable in minutes.
- Side-by-side charts that turn Calidi Biotherapeutics earnings report filing analysis into trend insights.
Trying to decode stock grants buried in the DEF 14A? Our summary of the Calidi Biotherapeutics proxy statement executive compensation highlights option pricing and performance hurdles. Need context on a sudden share sale? The platform tags each Calidi Biotherapeutics executive stock transactions Form 4 against trial timelines for true signal versus noise.
From “understanding Calidi Biotherapeutics SEC documents with AI” to tracking every Calidi Biotherapeutics insider trading Form 4 transactions, Stock Titan provides comprehensive coverage, updated the second the filing posts. Complex biotech filings, explained simply—so you can focus on decisions, not document hunts.
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) has filed a Form S-1 to register 6,355,650 shares of common stock for resale by existing holders. The bulk of the shares (6,053,000) are issuable upon exercise of Series G common warrants at an exercise price of $0.6954 per share (first exercisable 28 Sep 2025; expire 28 Mar 2033). A further 302,650 shares relate to warrants issued to placement agent Ladenburg Thalmann at $0.8125 per share (same first exercise date; expire 28 Sep 2030).
The company will not receive proceeds from the resale; cash would only be generated if warrant holders exercise for cash. At the last reported price of $0.2339 (2 Jul 2025) the warrants are out-of-the-money, but their future exercise could raise capital and dilute existing holders.
Calidi remains an emerging growth and smaller reporting company. It is also seeking shareholder approval to implement a reverse stock split between 1-for-2 and 1-for-19, after which historical share data will be adjusted.
Business profile. Calidi is a clinical-stage biotech developing three immuno-oncology platforms: RedTail (engineered vaccinia virus for systemic delivery of genetic medicines), SuperNova and NeuroNova (stem-cell-based oncolytic virus platforms). Lead candidate CLD-401 (IL-15 super-agonist payload) is targeted to enter Phase I by end-2026. The company currently has no approved products or revenue and highlights the need for substantial additional funding.
Governance changes. Former CEO & Chairman Allan Camaisa resigned effective 22 Apr 2025, becoming “CEO Emeritus” and remaining a Class III director. Eric Poma, Ph.D. was appointed CEO and Class I director, and James Schoeneck became Chairman. Camaisa receives a $500,000 12-month separation package plus consulting and COBRA payments.
The prospectus reiterates extensive risk factors typical of early-stage biotech firms, including capital needs, clinical uncertainty and potential NYSE American listing compliance.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
What does Calidi Biotherapeutics specialize in?
What is unique about Calidi's technology?
What are Calidi's key clinical programs?
How does Calidi address metastatic cancers?
What other applications does Calidi's technology have?
Where is Calidi Biotherapeutics headquartered?
What challenges does Calidi face in its market?
How does Calidi's technology improve patient safety?
